The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Real-world analysis of the MOST study: factors impacting progression to MF in patients with ET
In this video, Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, discusses a real-world analysis of the MOST study (NCT02953704), which is evaluating disease progression to myelofibrosis (MF) in patients with essential thrombocythemia (ET). Dr Mesa gives an overview of factors contributing to disease progression, including time and white blood cell (WBC) count at baseline, and further comments on the limitations of this study. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Promedior, Incyte, Genetech, Abbvie, Samus, Celgene, Constellation, CTI BioPharma., a Sobi Company, Mays Cancer Center, NCI; Consultancy: Constellation, LaJolla Pharma, Sierra Onc, Novartis.
